Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression

New Phase II data show vast majority of patients experiencing no relapses or disability progression

Tolebrutinib meets primary endpoint in HERCULES phase 3 study

Phase 3 study results will form the basis for future discussions with global regulatory authorities

Zydus receives warning letter from USFDA for Jarod injectables manufacturing facility

The company will take all necessary steps to work with USFDA towards earliest remediation of the above facility

Biocon Biologics secures market entry for Bmab 1200 in Europe, UK, Canada, and Japan

Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025

BI Sky Global successfully completes FDA MoCRA registration

MoCRA mandates that all facilities involved in the manufacturing and processing of cosmetic products for sale in the United States

Alembic receives FDA final approval for Betamethasone Valerate Foam, 0.12%

Oblique Therapeutics and Eli Lilly to apply the AbiProt technology to generate antibodies to a high-value target

This partnership aims to accelerate research and development into innovative treatments and, if successful, will generate milestones and royalties

Wanbury bags safety awards for its API manufacturing site in Patalganga

These accolades highlight our unwavering commitment to maintaining the highest safety standards

Coveris ramps up security label protection to tackle retail theft and supply-chain protection

Coveris’ security labels also work seamlessly with self-checkouts where around 80% of retail sales now typically occur

Aayush Wellness enters nutraceutical market with Dreamy Sleep Gummies